Standard therapy of Mycobacterium avium complex pulmonary disease shows limited efficacy in an open source hollow fibre system that simulates human plasma and epithelial lining fluid pharmacokinetics

Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline

(2020) Charles L Daley et al.   CLINICAL INFECTIOUS DISEASES

Minocycline treatment for pulmonary Mycobacterium avium complex disease based on pharmacokinetics/pharmacodynamics and Bayesian framework mathematical models

(2019) Mike M Ruth et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Non-tuberculous mycobacterial pulmonary disease

(2019) Steven Cowman et al.   EUROPEAN RESPIRATORY JOURNAL

Omadacycline as a promising new agent for the treatment of infections with Mycobacterium abscessus

(2019) Hannelore I Bax et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Comparison of human monocyte derived macrophages and THP1-like macrophages as in vitro models for M. tuberculosis infection

(2019) Abhilasha Madhvi et al.   COMPARATIVE IMMUNOLOGY MICROBIOLOGY AND INFECTIOUS DISEASES

Is there a role for tedizolid in the treatment of non-tuberculous mycobacterial disease?

(2019) Mike Marvin Ruth et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Protein Binding of First-Line Antituberculosis Drugs

(2018) Wael A. Alghamdi et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Microbiologic Outcome of Interventions Against Mycobacterium avium Complex Pulmonary Disease

(2018) Roland Diel et al.   CHEST

Minimum inhibitory concentration distributions for Mycobacterium avium complex—towards evidence-based susceptibility breakpoints

(2017) Thomas Schön et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Linezolid as treatment for pulmonary Mycobacterium avium disease

(2017) Devyani Deshpande et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

A novel ceftazidime/avibactam, rifabutin, tedizolid and moxifloxacin (CARTM) regimen for pulmonary Mycobacterium avium disease

(2017) Devyani Deshpande et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Tedizolid is highly bactericidal in the treatment of pulmonary Mycobacterium avium complex disease

(2017) Devyani Deshpande et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Exposure to Total and Protein-Unbound Rifampin Is Not Affected by Malnutrition in Indonesian Tuberculosis Patients

(2015) L. H. M. te Brake et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

A pharmacometric pulmonary model predicting the extent and rate of distribution from plasma to epithelial lining fluid and alveolar cells—using rifampicin as an example

(2015) Oskar Clewe et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Time–kill kinetics of slowly growing mycobacteria common in pulmonary disease

(2015) Beatriz E. Ferro et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Macrolide/Azalide Therapy for Nodular/Bronchiectatic Mycobacterium avium Complex Lung Disease

(2014) Richard J. Wallace et al.   CHEST

Blood, Tissue, and Intracellular Concentrations of Azithromycin during and after End of Therapy

(2013) P. Matzneller et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Drug treatment of pulmonary nontuberculous mycobacterial disease in HIV-negative patients: the evidence

(2013) Jakko van Ingen et al.   Expert Review of Anti-Infective Therapy

Pharmacokinetic studies in patients with nontuberculous mycobacterial lung infections

(2013) C. Magis-Escurra et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

The Pharmacokinetics and Pharmacodynamics of PulmonaryMycobacterium aviumComplex Disease Treatment

(2012) Jakko van Ingen et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

ESX-1-mediated translocation to the cytosol controls virulence of mycobacteria

(2012) Diane Houben et al.   CELLULAR MICROBIOLOGY